GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 Mar 2023 04:26 PM
RNS
GSK Annual Report 2022 on Form 20-F
10 Mar 2023 10:36 AM
RNS
GSK publishes Annual Report 2022
02 Mar 2023 07:00 AM
RNS
FDA Ad Com votes to support GSK RSV OA vaccine
01 Mar 2023 03:00 PM
RNS
Total Voting Rights
27 Feb 2023 03:30 PM
RNS
Director/PDMR Shareholding
23 Feb 2023 03:30 PM
RNS
Director/PDMR Shareholding
23 Feb 2023 07:00 AM
RNS
ViiV Healthcare announces Cabenuva positive data
22 Feb 2023 03:30 PM
RNS
Director/PDMR Shareholding
16 Feb 2023 07:00 AM
RNS
NEJM publishes GSK RSV OA vaccine candidate trial
15 Feb 2023 04:04 PM
RNS
Director/PDMR Shareholding
15 Feb 2023 04:00 PM
RNS
Director/PDMR Shareholding
14 Feb 2023 07:00 AM
RNS
Director/PDMR Shareholding
14 Feb 2023 07:00 AM
RNS
Director/PDMR Shareholding
14 Feb 2023 07:00 AM
RNS
Director/PDMR Shareholding
14 Feb 2023 07:00 AM
RNS
Director/PDMR Shareholding
10 Feb 2023 03:30 PM
RNS
Director/PDMR Shareholding
10 Feb 2023 07:05 AM
RNS
Jemperli full FDA approval following GARNET trial
10 Feb 2023 07:00 AM
RNS
Jemperli FDA ODAC positive outcome
02 Feb 2023 07:00 AM
RNS
Daprodustat approved by US FDA for anaemia of CKD
01 Feb 2023 03:30 PM
RNS
Director/PDMR Shareholding
01 Feb 2023 03:00 PM
RNS
Total Voting Rights
01 Feb 2023 07:05 AM
RNS
Benlysta granted Orphan Drug Designation by US FDA
01 Feb 2023 07:00 AM
RNS
Final Results
18 Jan 2023 03:30 PM
RNS
Director/PDMR Shareholding
17 Jan 2023 03:30 PM
RNS
Director/PDMR Shareholding
16 Jan 2023 03:30 PM
RNS
Director/PDMR Shareholding
13 Jan 2023 03:30 PM
RNS
Director/PDMR Shareholding
12 Jan 2023 03:30 PM
RNS
Director/PDMR Shareholding
03 Jan 2023 03:00 PM
RNS
Total Voting Rights
22 Dec 2022 03:30 PM
RNS
Director/PDMR Shareholding
21 Dec 2022 03:35 PM
RNS
Director/PDMR Shareholding
21 Dec 2022 03:30 PM
RNS
Director/PDMR Shareholding
15 Dec 2022 03:30 PM
RNS
Board and Committee Changes
13 Dec 2022 03:30 PM
RNS
Director/PDMR Shareholding
07 Dec 2022 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
05 Dec 2022 04:00 PM
RNS
Transfer of Treasury Shares
02 Dec 2022 03:30 PM
RNS
Director/PDMR Shareholding
02 Dec 2022 07:00 AM
RNS
EMA file accepted for momelotinib
02 Dec 2022 07:00 AM
RNS
Jemperli positive trial in endometrial cancer
01 Dec 2022 03:00 PM
RNS
Total Voting Rights
24 Nov 2022 03:00 PM
RNS
GSK publishes provisional 2023 dividend dates
22 Nov 2022 07:00 AM
RNS
Blenrep US Update
21 Nov 2022 03:30 PM
RNS
Director/PDMR Shareholding
15 Nov 2022 04:00 PM
RNS
Block listing Interim Review
11 Nov 2022 07:00 AM
RNS
GSK Update: Zejula 2L in US
10 Nov 2022 06:10 PM
RNS
Sanofi-GSK COVID booster vaccine approved by EU
10 Nov 2022 03:30 PM
RNS
Director/PDMR Shareholding
10 Nov 2022 09:00 AM
RNS
Block Listing Application
07 Nov 2022 07:00 AM
RNS
DREAMM-3 phase III trial for Blenrep
03 Nov 2022 07:00 AM
RNS
IDMC recommends gepotidacin early efficacy stop

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings